NASDAQ:INMDInMode Stock Price, Forecast & News

InMode's stock was trading at $24.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INMD stock has increased by 17.3% and is now trading at $28.61. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InMode.

InMode is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for InMode.

InMode Ltd. (NASDAQ:INMD) announced its earnings results on Wednesday, May, 6th. The healthcare company reported $0.30 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by $0.02. The healthcare company earned $40.44 million during the quarter, compared to the consensus estimate of $38.96 million. InMode had a return on equity of 37.88% and a net margin of 34.56%. InMode's revenue for the quarter was up 32.4% on a year-over-year basis. During the same period last year, the firm earned $0.29 EPS. View InMode's earnings history.

4 Wall Street analysts have issued 1 year price targets for InMode's stock. Their forecasts range from $36.00 to $55.00. On average, they expect InMode's stock price to reach $43.25 in the next year. This suggests a possible upside of 51.2% from the stock's current price. View analysts' price targets for InMode.

News articles about INMD stock have trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. InMode earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the healthcare company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutInMode.

InMode saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,570,000 shares, a decline of 29.9% from the April 30th total of 2,240,000 shares. Based on an average daily trading volume, of 1,370,000 shares, the short-interest ratio is presently 1.1 days. Currently, 11.4% of the shares of the company are sold short. View InMode's Current Options Chain.

Some companies that are related to InMode include LivaNova (LIVN), CONMED (CNMD), Natus Medical (NTUS), Zynex (ZYXI), AxoGen (AXGN), TransMedics Group (TMDX), BioLife Solutions (BLFS), Stereotaxis (STXS), BioSig Technologies (BSGM), Semler Scientific (SMLR), Viewray (VRAY), Cutera (CUTR), Soleno Therapeutics (SLNO), Fonar (FONR) and Edap Tms (EDAP). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), salesforce.com (CRM), Trade Desk (TTD), AbbVie (ABBV), Alteryx (AYX), Micron Technology (MU), Okta (OKTA) and Square (SQ).

(INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity acted as the underwriters for the IPO and Baird was co-manager.

InMode trades on the NASDAQ under the ticker symbol "INMD."

InMode's stock is owned by a number of institutional and retail investors. Top institutional investors include Wasatch Advisors Inc. (1.31%), Avalon Investment & Advisory (0.41%), Morgan Stanley (0.40%), Morgan Stanley (0.40%), UBS Group AG (0.31%) and Two Sigma Investments LP (0.29%).

INMD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Wells Fargo & Company MN, Mackenzie Financial Corp, UBS Group AG, JPMorgan Chase & Co., Steward Partners Investment Advisory LLC, and Fred Alger Management LLC.

INMD stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Two Sigma Investments LP, Axel Capital Management LLC, Avalon Investment & Advisory, Roubaix Capital LLC, Federated Hermes Inc., Geode Capital Management LLC, and Phoenix Holdings Ltd..

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INMD stock can currently be purchased for approximately $28.61.

InMode has a market capitalization of $914.75 million and generates $156.36 million in revenue each year. The healthcare company earns $61.15 million in net income (profit) each year or $1.60 on an earnings per share basis. InMode employs 198 workers across the globe.

The official website for InMode is www.inmodemd.com.

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]